Загрузка...
PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers
Several clinical trials are investigating the use of immune-targeted therapy with Programmed death ligand-1 (PD-L1) inhibitors for colorectal cancer (CRC), with promising results for patients with mismatch repair (MMR) deficiency or metastatic CRC. However, the prognostic significance of PD-L1 expre...
Сохранить в:
| Опубликовано в: : | J Pers Med |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7911042/ https://ncbi.nlm.nih.gov/pubmed/33530623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11020073 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|